Dianthus Therapeutics’ (DNTH) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $36.00 target price on the stock. Wedbush also issued estimates for Dianthus Therapeutics’ Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.11) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($2.75) EPS and FY2029 earnings at $1.79 EPS.

Other analysts have also issued reports about the stock. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

Shares of NASDAQ DNTH opened at $21.33 on Wednesday. The firm’s 50-day moving average price is $22.61 and its 200-day moving average price is $24.92. The stock has a market capitalization of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNTH. TCG Crossover Management LLC bought a new position in Dianthus Therapeutics in the 4th quarter worth about $32,735,000. Braidwell LP boosted its stake in shares of Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after purchasing an additional 712,902 shares in the last quarter. Vestal Point Capital LP lifted its position in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after acquiring an additional 680,000 shares during the last quarter. State Street Corp lifted its position in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Finally, Octagon Capital Advisors LP lifted its position in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after acquiring an additional 363,500 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.